Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 93Stomach Neoplasms 56Rectal Neoplasms 51Colonic Neoplasms 47Pancreatic Neoplasms 21Neoplasms 14Carcinoma, Hepatocellular 14Neoplasm Metastasis 13Adenocarcinoma 10Parkinson Disease 4, Autosomal Dominant Lewy Body 9Lymphoma, Large B-Cell, Diffuse 9Cholangiocarcinoma 8Adenocarcinoma Of Esophagus 8Esophageal Neoplasms 5Biliary Tract Neoplasms 5Neurotoxicity Syndromes 4Esophageal Squamous Cell Carcinoma 4Lymphoma, Extranodal NK-T-Cell 3Gastrointestinal Neoplasms 3Gallbladder Neoplasms 3Peritoneal Neoplasms 2Lymphoma 2Liver Neoplasms 2Hepatoblastoma 2Gastrointestinal Diseases 2Colorectal Adenocarcinoma 2Testicular Neoplasms 1Testicular Germ Cell Tumor 1Teratoma 1Spinocerebellar Degenerations 1

Interventions

folfirinox 1devimistat 1Paclitaxel 1Oxaliplatin 1Leucovorin 1Irinotecan 1Injections 1Gemcitabine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Pancreatic Cancer Metastatic × Oxaliplatin × Clear all
NCT03504423 2023-01-03

Study Evaluating Efficacy and Safety of FFX Versus Combination of CPI-613 With mFFX in Patients With Metastatic Adenocarcinoma of the Pancreas

Cornerstone Pharmaceuticals

Phase 3 Completed
528 enrolled 11 charts
Gastrointestinal

Pancreatic Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡